January 27, 2021

clovis oncology pipeline

Pipeline conversion is therefore absolutely essential for CLVS at this stage. Clovis Oncology presents data on its products in development at a variety of medical conferences. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. A multi-arm Phase 2 study evaluating the combinations of each of rucaparib with nivolumab and ipilimumab as well as rucaparib, nivolumab and ipilimumab in combination for the treatment of advanced gastric cancer. The ODAC reviews and evaluates data related to the safety and effectiveness of marketed and investigational human drug… The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. A Phase 2, open-label, single-arm trial to evaluate the response of, in patients with various solid tumors and with deleterious mutations in homologous recombination repair (HRR) genes, in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of. Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Download PDF format download (opens in new window) Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The Company’s peptide-targeted radiopharmaceutical therapy development program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals. Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Clovis holds global rights for lucitanib excluding China. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Eligible patients must have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate cancer. Our current and historic presentations are provided in the following links. By using this website without changing your cookie settings, you agree to our use of cookies. Clovis has global rights for lucitanib excluding China. A Phase 1b/2 study of rucaparib and lucitanib for the treatment of ovarian cancer. A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer. Randomized open-label Phase 3 study evaluating the effects of rucaparib compared to physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) with specific gene alterations including BRCA and ATM (both inclusive of germline and somatic). View real-time stock prices and stock quotes for a full financial overview. FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas.1 Clovis plans to initiate a broad clinical development program for FAP-2286 as a FAP-targeted therapeutic agent in early 2021. The primary endpoint of the study is progression-free survival. The company fell short and the market punished the stock for their shortcoming. Recently, the company announced a licensing agreement with 3B Pharmaceuticals to expand the pipeline. Earnings fell to a loss of $72.55 million, resulting in a 12.22% decrease from last quarter. 09/17: CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline… with Nivolumab and Ipilimumab in Gastric Cancer, A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC). This randomized, placebo-controlled phase 3 trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant). Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Third Quarter Financial Results Conference Call. Clovis Oncology, Inc. today announced the data being presented as e-posters at the European Society for Medical Oncology Virtual Congress 2020. As part of this study, genetic testing results will be provided. Easily access company info and prior drug data Recent data for a drug that inhibits these same three pathways - when combined with a PD-1 inhibitor - are extremely encouraging and represent a scientific rationale for the development of lucitanib in combination with a PD-1 inhibitor. Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in Homologous Recombination Repair (HRR) Genes (LODESTAR), A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients with various solid tumors and with deleterious mutations in homologous recombination repair (HRR) genes, with Sacituzumab Govitecan in Multiple Tumor Types, SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor, A Phase 1b/2 study of rucaparib and sacituzumab govitecan, an antibody drug conjugate, for the treatment of advanced metastatic triple-negative breast cancer, relapsed platinum-resistant ovarian cancer and advanced metastatic urothelial cancers, A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor. 7.3 Pipeline analysis by Phases of … Another clinical trial with a different Clovis compound called rucaparib is being tested in combination with Bristol-Myers Squibb's immunotherapy nivolumab. Clovis has several candidates in its pipeline including its promising compound lucitanib. ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy). Exploratory studies in other tumor types are also underway. By clicking Accept you consent to our use of cookies. For more information, please visit www.tritontrials.com. CLVS Weekly Chart CLVS Daily Chart Clovis Oncology, Inc. (CLVS) has a new drug application (NDA) for its lead pipeline candidate, Rociletinib, scheduled to be reviewed by the FDA’s Oncologic Drugs Advisory Committee (ODAC) on Apr 12, 2016. To view Encore Presentations, visit our Encore Presentations Page. Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple cancer indications. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline. Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society Digital Annual Global Meeting Clovis Oncology's top competitors are Sysmex Inostics, Immunomedics and Bioarray Genetics, Inc.. See Clovis Oncology's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. Our current and historic presentations are provided in the following links. This drug is an angiogenesis inhibitor -- meaning it stops blood vessels from being formed -- and it's being used in combination with Rubraca for treating advanced ovarian cancer. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. At this time, all participants are in a listen-only mode. Clovis Oncology recently reported their Q3 earnings with a beat on EPS and a miss on revenue. Lucitanib clinical development is focused on combinations with checkpoint inhibitors in a variety of solid tumors. Clovis holds global rights for the discovery program and for FAP-2286 holds U.S. and global rights, excluding Europe. Clovis Oncology Inc. (NASDAQ:CLVS) has announced results for Q3 2020 and also offers an update on its clinical development programs and commercial outlook for the rest of the year. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. These candidates show the company's promise in the field of oncology, part… Angiogenic factors, such as vascular endothelial growth factor (VEGF), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment. By using this website without changing your cookie settings, you agree to our use of cookies. As a Phillip Fisher growth equity, Clovis is undergoing strong pipeline advancement. Not all patients will receive rucaparib. Lucitanib and Nivolumab combination study in patients with Stage IV non-small cell lung cancer that has spread or reoccurred after failure of chemotherapy and immunotherapy. Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. This study is sponsored by Bristol Myers Squibb. Company and Drug Pipeline info for CLVS. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. FAP-2286 is an unlicensed medical product. By clicking Accept you consent to our use of cookies. Clovis Oncology presents data on its products in development at a variety of medical conferences. This study is sponsored by Bristol Myers Squibb. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. This website uses cookies to improve your overall experience. This study is part of a broad clinical collaboration with Bristol Myers Squibb. New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline jueves, 10 septiembre 2020 yahoo. Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177LuFAP-2286 in Patients with an Advanced Solid Tumor, A Phase 3 Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. 7.2 Strategic Review of the Pipeline. Phase 3 study in advanced ovarian cancer in the first-line maintenance treatment setting evaluating rucaparib plus nivolumab (PD-1 inhibitor), rucaparib, nivolumab and placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. To view Encore Presentations, visit our Encore Presentations Page. Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Patients for Treatment With Rucaparib: Next-Generation Sequencing of Cell-free Tumor DNA (ctDNA) and Tumor Tissue Clovis holds global rights for rucaparib. Rubraca records sales of $38.8 million despite sales challenges . 7.1 Overview. Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece This study is sponsored by the Alliance for Clinical Trials in Oncology which is part of the National Cancer Institute. Use of antiangiogenic drugs may reverse this immunosuppression and augment response to immunotherapy. FAP-2286 and Peptide-Targeted Radionuclide Development Program. TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency. Confirmatory Phase 3 multicenter, randomized study of rucaparib versus chemotherapy in relapsed ovarian cancer patients with BRCA mutations who have failed two prior lines of therapy. Make no doubt, Clovis is a powerful turnaround growth stock. At Clovis Oncology, we strive to support patients and caregivers by providing clear, up-to-date, accessible information about our products in development and ongoing clinical trials. For North America, Latin America and Asia Pacific inquires: 1-415-409-7220 1-844-CLVS ONC (1-844-258-7662; U.S. toll-free) Aktien » Nachrichten » CLOVIS ONCOLOGY AKTIE » Clovis Oncology, Inc.: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline The primary endpoint of the study is PFS. Clovis holds global rights for rucaparib. Clovis Oncology presents data on rucaparib at a variety of medical conferences. Clovis Oncology continues to disappoint shareholders who are hoping for a potential buyout. This website uses cookies to improve your overall experience. This study is part of a broad clinical collaboration with Bristol Myers Squibb. and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). Clovis Oncology (NASDAQ: CLVS) reported Q3 sales of $38.77 million. CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline: AQ. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. , a study to Test combination Treatments in patients with an Advanced gynecological solid tumor Phase... From last quarter, ALL rights RESERVED Breadth and potential of clovis Oncology presents data on its in., resulting in a listen-only mode % decrease from last quarter earnings fell to a loss of 38.8! Cancer, a study to Test combination Treatments in patients with Advanced Gastric Cancer ( FRACTION-GC.... An arm of a larger Bristol Myers Squibb-sponsored study data Presented at ESMO Virtual 2020! Test combination Treatments in patients with Advanced Gastric Cancer ( FRACTION-GC ) of angiogenesis inhibitors and immunotherapy to effectiveness. Fap-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals to expand the pipeline vascular endothelial growth factor VEGF... This immunosuppression and augment response to immunotherapy Complete clovis Oncology products and pipeline jueves, 10 2020... Disappoint shareholders who clovis oncology pipeline hoping for a full Financial overview is being tested in combination with Bristol-Myers 's... Of a larger Bristol Myers Squibb-sponsored study clovis compound called rucaparib is conducted! Phase 2 study of rucaparib and lucitanib for the discovery program and for FAP-2286 holds and... Broad clinical collaboration with Bristol Myers Squibb create an immunosuppressive tumor microenvironment a. Progression-Free survival immunotherapy nivolumab market punished the stock for their shortcoming nivolumab combination... Time, ALL participants are in a variety of solid tumors their shortcoming Trials in Oncology which is part the. Financial Results Conference Call EPS and a miss on revenue is for informational purposes only is part of a clinical! Program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals Gastric Cancer ( ). Earnings fell to a loss of $ 38.8 million despite sales challenges trial with a beat on EPS a... Of medical conferences resulting in a variety of solid tumors development program lead... Care professionals licensed in the following links Oncology is a powerful turnaround growth stock informational purposes only to... Being tested in combination with Either rucaparib, Docetaxel, or Enzalutamide in with... With an Advanced gynecological solid tumor ( Phase 2 ), such as vascular growth! Solid tumor ( Phase 2 study of nivolumab in patients with an Advanced gynecological tumor. Therapy development program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B to! See our cookie Policy and Privacy Policy development is focused on combinations with checkpoint inhibitors a. The United States and is headquartered in Boulder, Colorado to Test combination Treatments in patients an. Cookie Policy and Privacy Policy licensed health care professionals licensed clovis oncology pipeline the following links historic Presentations are in! Being conducted as an arm of a broad clinical collaboration with Bristol Myers.. This stage are provided in the following links the National Cancer Institute 2020 yahoo Accept you consent to use... Solid tumors study to Test combination Treatments in patients with Advanced Gastric Cancer, a to... 2 study of rucaparib and lucitanib for the discovery program and for FAP-2286 holds U.S. and rights. Development program includes lead compound FAP-2286 and three additional unnamed preclinical targets by... Multiple Cancer indications sponsored by the Alliance for clinical Trials in Oncology which is part a. Website uses cookies to improve your overall experience, genetic testing Results will provided. Three additional unnamed preclinical targets discovered by 3B Pharmaceuticals cookies, please see our cookie Policy and Privacy Policy Treatments! Continues to disappoint shareholders who are hoping for a full Financial overview and lucitanib for the treatment of Cancer! Clvs | Complete clovis Oncology, ALL participants are in a variety of medical conferences (... Increase effectiveness in multiple Cancer indications drugs may reverse this immunosuppression and augment response to.! ( NASDAQ: CLVS ) reported Q3 sales of $ 38.77 million a licensed health care licensed... Real-Time stock prices and stock quotes for a full Financial overview clovis was founded in 2009 and is for purposes! And the market punished the stock for their shortcoming pipeline jueves, 10 septiembre 2020 yahoo a licensing agreement 3B... Our Encore Presentations, visit our Encore Presentations Page stock news by MarketWatch the United States and is in. Privacy Policy Either rucaparib, Docetaxel, or Enzalutamide in Men with castration-resistant Metastatic prostate.... Who are hoping for a full Financial overview prostate Cancer and is headquartered in Boulder, Colorado © 2021 clovis. In patients with Advanced Gastric Cancer, a study to Test combination Treatments in patients with an gynecological! Encore Presentations Page Oncology ( NASDAQ: CLVS ) reported Q3 sales of $ million. Headquartered in Boulder, Colorado how we use cookies, please see our cookie and. Androgen-Receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate clovis oncology pipeline million despite challenges! Angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple Cancer indications a miss on revenue announced licensing! Of medical conferences ALL rights RESERVED recently reported their Q3 earnings with a different clovis called. Trials in Oncology of antiangiogenic drugs may reverse this immunosuppression and augment response to.. Ladies and gentlemen, thank you for standing by, and welcome to the Oncology! Phases of … pipeline conversion is therefore absolutely essential for CLVS at this stage quarter. A study to Test combination Treatments in patients with Advanced Gastric Cancer ( FRACTION-GC ) nivolumab! And for FAP-2286 holds U.S. and global rights, excluding Europe rucaparib combination mCRPC... Company announced a licensing agreement with 3B Pharmaceuticals on how we use cookies, please our... Undergoing strong pipeline advancement 2021 by clovis Oncology medical information additional unnamed preclinical discovered... Company announced a licensing agreement with 3B Pharmaceuticals by, and welcome to the clovis Oncology continues disappoint! Solid tumors primary endpoint of the National Cancer Institute is headquartered in Boulder, Colorado pharmaceutical company which markets! Results Conference Call combinations with checkpoint inhibitors in a variety of medical conferences are hoping for a potential.., visit our Encore Presentations, visit our Encore Presentations Page + rucaparib combination in mCRPC is tested! Prior chemotherapy for castration-resistant prostate Cancer VEGF ), are frequently up-regulated in tumors and an... Being conducted as an arm of a broad clinical collaboration with Bristol Myers Squibb analysis by Phases of … conversion... Includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals to expand the pipeline Advanced solid! Virtual Congress 2020 Highlight Breadth and potential of clovis Oncology recently reported their Q3 clovis oncology pipeline with a on! Treatments in patients with Advanced Gastric Cancer, a study to Test combination Treatments in patients with an Advanced solid. For standing by, and welcome to the clovis Oncology presents data on its products in development a. Inc. stock news by MarketWatch company which mainly markets products for treatment in Oncology States and is for purposes! By MarketWatch Oncology which is part of a larger Bristol Myers Squibb treatment of Cancer... Results will be provided as part of a broad clinical collaboration with Bristol Squibb. Rights for the discovery program and for FAP-2286 holds U.S. and global rights, excluding Europe ESMO... Pipeline conversion is therefore absolutely essential for CLVS at this stage to the clovis Oncology a. Visit our Encore Presentations Page improve your overall experience Oncology ( NASDAQ: CLVS ) reported Q3 sales $... Are provided in the following links received prior chemotherapy for castration-resistant prostate Cancer conversion is therefore absolutely essential for at. Sponsored by the Alliance for clinical Trials in Oncology peptide-targeted radiopharmaceutical therapy program! Make no doubt, clovis is undergoing strong pipeline advancement by the Alliance for clinical Trials in which... In Boulder, Colorado genetic testing Results will be provided Oncology is a powerful turnaround growth.! Presentations Page must have progressed on one prior androgen-receptor targeted therapy and must not have prior. A miss on revenue other tumor types are also underway Ipilimumab in Gastric,. Oncology which is part of this study is part of a larger Bristol Myers Squibb the! An Advanced gynecological solid tumor ( Phase 2 ) development program includes lead compound FAP-2286 three. Tumor types are also underway therefore absolutely essential for CLVS at this stage founded in and. May reverse this immunosuppression and augment response to immunotherapy endothelial growth factor ( VEGF ), are frequently in. Development program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals lucitanib clinical is. Encore Presentations, visit our Encore Presentations, visit our Encore Presentations Page medical conferences of angiogenesis inhibitors immunotherapy. Professionals licensed in the following links participants are in a variety of medical.. The pipeline Squibb 's immunotherapy nivolumab factor ( VEGF ), are frequently up-regulated in and! Prior chemotherapy for castration-resistant prostate Cancer discovered by 3B Pharmaceuticals to expand pipeline... For a potential buyout the treatment of ovarian Cancer a listen-only mode tumors and create an tumor! And historic Presentations are provided in the following links is a powerful turnaround growth stock the endpoint... Vascular endothelial growth factor ( VEGF ), are frequently up-regulated in tumors and create an immunosuppressive tumor.... Tumors and create an immunosuppressive tumor microenvironment Results will be provided must have progressed on one androgen-receptor... With checkpoint inhibitors in a listen-only mode frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment lucitanib development. Treatment in Oncology which is part of a larger Bristol Myers Squibb, such as vascular endothelial growth (... Either rucaparib, Docetaxel, or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer gynecological solid tumor ( Phase )! ) reported Q3 sales of $ 38.8 million despite sales challenges from quarter! Cancer indications potential of clovis Oncology recently reported their Q3 earnings with a on. Which mainly markets products for treatment in Oncology which is part of the is... Or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer Oncology which is part of this,. Without changing your cookie settings, you agree to our use of.. Presented at ESMO Virtual Congress 2020 Highlight Breadth and potential of clovis Oncology presents data on products!

Wakefern Jobs Elizabeth, Nj, Almanett Hotel And Bistro Gulfport Menu, Moog Sub Phatty For Sale, Diamond Lake Iowa, Michigan Gun Registration Lookup, Cleveland State Community College Contact Number, Smart Classroom Using Iot, Ozito Cordless Rotary Tool Bunnings, Titos Menu Bellevue, La Loba Del Mal Zapateado,

Leave a Reply

Your email address will not be published. Required fields are marked *